ASRM, Leading Reproductive Health Organizations Attend HHS Policy Convening on Hormone Replacement Therapy (HRT)

November 11, 2025
For Immediate Release

Washington, DC—ASRM CEO Dr. Jared Robins joined colleagues from the American College of Obstetricians and Gynecologists (ACOG), the Endocrine Society, the Menopause Society, and the American Urological Association (AUA) along with others yesterday in attending an event hosted by Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. and FDA Commissioner Marty Makary, MD, MPH to announce a major change to the regulation of exogenous estrogen therapy.

During the event, held at HHS headquarters in Washington, D.C., the Secretary unveiled a new policy that removes the so-called “black box warnings” previously required on all estrogen products. “We are pleased that Secretary Kennedy and Commissioner Makary invited us to be part of this event and hope that this is the start of a new relationship between the administration and ASRM. Our members have expertise in all aspects of reproductive medicine, including fertility care, contraception, menopause, and reproductive endocrinology. We look forward to working with the government so that they may take advantage of that knowledge to develop policies that will improve America’s reproductive health,” said Dr. Robins.

Dr. Robins added, “Many aspects of this change were past due, and we are encouraged that it will allow patients and physicians to determine the best treatment for each individual. We applaud the FDA for its focus on advancing women’s health, assembling a task force of physicians who treat women, and following a formal notice-and-comment process. However, while we are happy with the decision, we are concerned that the well-established and successful Advisory Committee system, which provides systematic and independent peer review, was not utilized. Policy makers and medical experts working together can use the best empirical and data-driven research to ensure Americans have access to scientifically proven treatments, while protecting them from those who might seek to exploit their vulnerability, or who would want to insert themselves in the medical decision-making process.”